These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24369839)

  • 1. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.
    Suda A; Kawasaki K; Komiyama S; Isshiki Y; Yoon DO; Kim SJ; Na YJ; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem; 2014 Jan; 22(2):892-905. PubMed ID: 24369839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.
    Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
    Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
    Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.
    Davies NG; Browne H; Davis B; Drysdale MJ; Foloppe N; Geoffrey S; Gibbons B; Hart T; Hubbard R; Jensen MR; Mansell H; Massey A; Matassova N; Moore JD; Murray J; Pratt R; Ray S; Robertson A; Roughley SD; Schoepfer J; Scriven K; Simmonite H; Stokes S; Surgenor A; Webb P; Wood M; Wright L; Brough P
    Bioorg Med Chem; 2012 Nov; 20(22):6770-89. PubMed ID: 23018093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
    Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
    J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.
    Woodhead AJ; Angove H; Carr MG; Chessari G; Congreve M; Coyle JE; Cosme J; Graham B; Day PJ; Downham R; Fazal L; Feltell R; Figueroa E; Frederickson M; Lewis J; McMenamin R; Murray CW; O'Brien MA; Parra L; Patel S; Phillips T; Rees DC; Rich S; Smith DM; Trewartha G; Vinkovic M; Williams B; Woolford AJ
    J Med Chem; 2010 Aug; 53(16):5956-69. PubMed ID: 20662534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
    Uno T; Kawai Y; Yamashita S; Oshiumi H; Yoshimura C; Mizutani T; Suzuki T; Chong KT; Shigeno K; Ohkubo M; Kodama Y; Muraoka H; Funabashi K; Takahashi K; Ohkubo S; Kitade M
    J Med Chem; 2019 Jan; 62(2):531-551. PubMed ID: 30525599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors.
    Lee JH; Shin SC; Seo SH; Seo YH; Jeong N; Kim CW; Kim EE; Keum G
    Bioorg Med Chem Lett; 2017 Jan; 27(2):237-241. PubMed ID: 27914802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
    Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.
    Jiang F; Guo AP; Xu JC; Wang HJ; Mo XF; You QD; Xu XL
    Eur J Med Chem; 2017 Dec; 141():1-14. PubMed ID: 29028527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
    Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
    J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.
    Zhang L; Fan J; Vu K; Hong K; Le Brazidec JY; Shi J; Biamonte M; Busch DJ; Lough RE; Grecko R; Ran Y; Sensintaffar JL; Kamal A; Lundgren K; Burrows FJ; Mansfield R; Timony GA; Ulm EH; Kasibhatla SR; Boehm MF
    J Med Chem; 2006 Aug; 49(17):5352-62. PubMed ID: 16913725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
    Jung J; Kwon J; Hong S; Moon AN; Jeong J; Kwon S; Kim JA; Lee M; Lee H; Lee JH; Lee J
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127165. PubMed ID: 32305165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.